Research Argenx heads to FDA with Vyvgart after ph. 3 win in potential blockbuster autoimmune indicationBy Healthcare Propulsion StaffAugust 17, 20260 With its latest trial readout for under-the-skin efgartigimod, argenx is adding another feather to the FcRn blocker’s cap. On Monday,…
